Kala Bio, Inc. (KALA): Operating Income
-$39.16M
Year ended 2025-12-31
-$20.99M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$39.16M | n/m | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | -$40.98M | n/m | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | -$39.66M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$81.71M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$130.25M | n/m | 2023-03-03, From 2021-01-01 |
| 2020-12-31 | -$96.23M | n/m | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$88.22M | n/m | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | -$64.72M | n/m | 2020-02-12, From 2018-01-01 |
| 2017-12-31 | -$39.88M | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | -$32.67M | n/m | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | -$15.95M | n/a | 2018-04-02, From 2015-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Kala Bio, Inc. (KALA) | 2025-12-31 | -$39.16M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.05B | +18.0% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.39M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $24.74M | +23.1% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | -$5.29M | n/m |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.21M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$2.54M | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $2.16B | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $231.0K | n/m |
Compare KALA, ABT, TXMD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗